Key genes such as ALB and TIMP1 emerged as central regulators of HBV-associated metabolic reprogramming and fibrosis, highlighting potential therapeutic targets for HBV-related liver disease (Figure 3F). The gene discussed is ALB; the disease is liver disorder.